FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?

Beep Beep. Hey intern the patient’s blood pressure is 160/95. Do you want to do something. No. The answer is no. But honestly we have all been guilted into ordering some clonidine or god forbid some IV hydralazine. Stop it. Just stop it. Join the filtrate as we dissect a recent study looking...